Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction

Aims:In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment. This study investigated the factors linked to up-titration of sacubitril/valsartan in patients with heart failure and preserved ejection fraction (HFpEF). Methods:Using a multicenter retrospective database, 204 consecutive patients with HFpEF (left ventricular ejection fraction >= 40%) who were treated with sacubitril/valsartan between October 2020 and March 2022 were analyzed. Up-titration was defined as an increase in dosage above 24/26 mg BID beyond 12 weeks after the initiation of sacubitril/valsartan. Results:Among the patients, 55% underwent up-titration, and 8% discontinued the drug. The baseline systolic blood pressure (SBP) was higher in patients with up-titration than in those with no up-titration; SBP values similar to that at baseline were observed between the 2 groups at 2 to 4 weeks and at 12 weeks after the commencement of sacubitril/valsartan treatment. The majority of those who discontinued sacubitril/valsartan did so because of hypotension. The multivariable logistic regression model showed that a history of hypertension, history of atrial fibrillation, baseline SBP, and baseline estimated glomerular filtration rate Conclusion:Approximately half of all patients did not undergo up-titration, and 8% of those with HFpEF discontinued the sacubitril/valsartan therapy. For aggressive up-titration and continuation of sacubitril/valsartan, patients with lower baseline SBP, renal dysfunction, absence of a history of hypertension, and presence of atrial fibrillation may require more careful monitoring.

Automated summary

This study investigates the factors associated with the up-titration of sacubitril/valsartan in patients with heart failure and preserved ejection fraction (HFpEF). The results showed that approximately half of the patients did not undergo up-titration, and 8% discontinued the therapy. Patients with lower baseline systolic blood pressure, renal dysfunction, absence of a history of hypertension, and presence of atrial fibrillation may require more careful monitoring for aggressive up-titration and continuation of sacubitril/valsartan.